Abstract
This study aimed to determine the clinicopathological features, treatment methods and prognosis in patients with malignant lymphoma of the oral cavity. We retrospectively examined 28 cases of malignant lymphoma of the oral cavity based on the novel World Health Organization pathological classification. The most common primary site was the upper gingival area (32.1%) and the most frequent initial symptom was painless swelling (48.5%); 7.1% of cases were stage III and 21.4% were stage IV according to the Ann Arbor classification. The most common histologic type was diffuse large B-cell lymphoma. Clinically, 14.3% of cases were classified as highly aggressive, and three-quarters of these cases were ulcerated. The most common type of chemotherapy was R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), which was used in 28.6% of patients. Five-year overall survival was 69.7% for all cases and 53.5% for those with diffuse large B-cell lymphoma. Patients with an Ann Arbor disease classification of stage III or IV and histologically aggressive disease are not uncommon and have poor prognosis. Therefore, prompt biopsy is needed for painless swelling of the upper gingiva to perform differential diagnosis of malignant lymphoma of the oral cavity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
